Why the study?
Is the retrievable and repositionable VenusA-Plus valve feasible for TAVR in a high-risk patient with a bicuspid aortic valve?
Is the retrievable and repositionable VenusA-Plus valve feasible for TAVR in a high-risk patient with a bicuspid aortic valve?
The first-in-man implantation demonstrates the feasibility of the retrievable and repositionable VenusA-Plus valve in a high-risk patient with a complex bicuspid aortic valve.
VenusA-Plus may be feasible in high-risk bicuspid TAVR; leaves open safety, efficacy, and durability for prospective confirmation.
BACKGROUND: No retrievable and repositionable second generation transcatheter aortic valve is available in China. Here, we report the first-in-man implantation of the retrievable and repositionable VenusA-Plus valve. METHODS: A 76-year-old patient with symptomatic severe aortic stenosis and high surgical risk (STS 13.8%) was recommended for transcatheter aortic valve replacement (TAVR) by heart valve team. Type 0 bicuspid aortic valve with asymmetric calcification was identified by dual source computed tomography, and the unfavorable anatomies increased the possibility of malposition and paravalvular leakage during TAVR. Therefore, we used the retrievable and repositionable VenusA-Plus valve for the patient. RESULTS: Transfemoral TAVR was performed under local anesthesia with sedation, and a 26mm VenusA-Plus valve was successfully implanted. No transvalvular pressure gradient and trace paravalvular leakage were found. CONCLUSION: The successful first-in-man implantation indicates the retrievable and repositionable VenusA-Plus valve is feasible in complicated TAVR cases such as bicuspid aortic valve.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: